

2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry for Samuele Cazzamalli, Head of Chemistry at Philochem

Dr. Samuele Cazzamalli, Head of Chemistry at Philochem, will be awarded the 2024 EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry

His research has focused on the discovery of novel tumor-targeting small molecule ligands through the use of DNA-Encoded Chemical Libraries

Siena (Italy), September, 4 2024 – Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, is pleased to announce that in recognition of his many years of research and industrial application of tumor-targeting small molecules, Samuele Cazzamalli will be awarded the 2024 European Federation for Medicinal Chemistry and Chemical Biology (EFMC) Prize for Young Medicinal Chemist or Chemical Biologist in Industry.

The EFMC Prize for Young Medicinal Chemist or Chemical Biologist in Industry is a prestigious annual prize given to outstanding young medicinal chemists working in industry. Dr. Cazzamalli was selected for this honor because of his outstanding contributions to the discovery of novel tumor-targeting small molecule ligands through DNA-Encoded Chemical Libraries. The ceremony will take place at the XXVIII EFMC International Symposium on Medicinal Chemistry 2024 in Rome during which Dr. Cazzamalli will give an oral presentation about his work.

Dr. Cazzamalli is currently the Head of Chemistry at Philochem, the Swiss subsidiary of the Philogen group that acts as a discovery center with a focus on chemical pharmaceutical products and technologies. Dr. Cazzamalli earned his PhD at ETH Zürich under the supervision of Prof. Dario Neri with a thesis on non-internalizing antibody- and small molecule-drug conjugates for the treatment of cancer. Dr. Cazzamalli has published more than 40 articles in international peer-reviewed journals and has brought three compounds in Phase I clinical trials.

Under Dr. Cazzamalli's leadership, his group at Philochem has isolated high-affinity small organic ligands from DNA-Encoded Chemical Libraries against various tumor-associated antigens. Through conjugation of these ligands to potent payloads such as cytotoxic drugs or radionuclides, Dr. Cazzamalli's group has developed a number of promising small molecule diagnostic and therapeutic compounds.

Philochem has successfully completed two Phase I clinical trials with novel small molecule radioligands and is launching three additional Phase I clinical trials this year. The company's success is the result of the group's extensive experience in both DNA-encoded chemical libraries and clinical trial management.

About Philochem and the Philogen Group

Philochem is a fully owned subsidiary of the Philogen Group, a Swiss-Italian, clinical-stage biotechnology company listed on the Italian Stock Exchange. Philogen is engaged in the discovery and development of novel pharmaceutical and biopharmaceutical products. Philogen's strategy is to selectively deliver bioactive agents (such as radionuclides, cytokines or drugs) to the site of disease using antibodies or small organic ligands. This technology has generated a strong proprietary pipeline of clinical-stage products and preclinical compounds in an array of disease indications. Philogen is headquartered in Siena, Italy, and has research activities at its subsidiary company Philochem near Zurich, Switzerland. Philogen has signed agreements with several major pharmaceutical companies. For more information, please visit www.philogen.com and www.philochem.ch.

* * *

FOR MORE INFORMATION:

Philogen - Investor Relations

IR@philogen.com - Emanuele Puca | Investor Relations